Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In Australia, glioblastoma (GBM) has a higher annual fatality rate than a variety of other cancers, such as melanoma, bladder, and kidney tumors. While the 5-year survival rate for other cancers, such as breast and prostate cancer, has increased, there have been no notable advancements in GBM during the past ten years, and the incidence and mortality patterns have barely changed between 1982 and 2011. In particular, GBM poses a challenging therapeutic dilemma for patients and physicians due to its aggressive biology and resistance to available treatments. Recent studies showed that cytomegalovirus (CMV) is expressed in GBM tumors, making it a good target for immunotherapy trials. This phase I trial aims to determine the safety and tolerability of the PEP-CMV vaccine in patients with newly diagnosed MGMT-unmethylated GBM in combination with one cycle of adjuvant temozolomide.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona histologicznie nowa diagnoza glejaka mózgu
- •Glejak bez metylacji MGMT
- •Dodatni wynik na wirusa CMV w badaniu krwi
- •Przebyta operacja chirurgiczna usuniająca całość lub część guza
- •Odbycie standardowego napromieniowania i chemioterapii temozolomidem
- •Sprawne funkcje wątroby, nerek i szpiku kostnego
- •Oczekiwana długość życia co najmniej 12 tygodni
✗ Disqualifies
- •Ciąża lub karmienie piersią (wymagany ujemny test ciążowy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Ingham Institute of Applied Medical Research
Liverpool, Australia
Scientia Clinical Research
Randwick, Australia
Trial contact
Charlotte Lemech
Regienald Gayaman
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.